Exelixis | EXEL - Ebitda



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 14.32B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


Ebitda 更改 日
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Bayer EUR 4.45B 2.49B 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Cytokinetics USD -169.32M 19.48M 2026-03
Eisai JPY -335M 30.43B 2026-03
Eli Lilly USD 12.14B 4.26B 2025-12
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Exelixis USD 258.29M 15.43M 2026-03
Genmab DKK 186M 291M 2025-12
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.3B 530M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Puma Biotechnology USD 729K 11.36M 2024-06
Sanofi EUR 5.66B 3.77B 2025-09
Takeda JPY 150.25B 297.88B 2026-03
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Xencor USD -51.05M 55.28M 2025-12